GlassScriptPhysician profile
Michelle L Deeves
NPI 1164622924
$8,994.93
in general payments reported to CMS, 2019-2025
60 companies · $1,018 in 2025
The $1,018 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,638 · 2020: $703 · 2021: $1,226 · 2022: $1,289 · 2023: $1,477 · 2024: $1,644 · 2025: $1,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,077 · Education: $62.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,076.86 |
| Education | $62.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,032.25 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,024.39 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $714.74 | 2019-2025 | Veozah |
| Abbvie INC. | $617.90 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Janssen Pharmaceuticals, INC | $506.89 | 2019-2021 | |
| Novo Nordisk INC | $480.88 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $465.28 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $434.43 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $421.29 | 2021-2025 | |
| Pfizer INC. | $393.40 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $233.03 | 2019-2024 | |
| Amgen INC. | $225.59 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.83 | 2019-2024 | Synjardy, Ofev, Tradjenta |
| Daiichi Sankyo INC. | $138.95 | 2022-2025 | Injectafer |
| Amarin Pharma, INC. | $120.53 | 2019-2021 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $107.73 | 2022 | |
| Lilly USA, LLC | $99.67 | 2019-2025 | Zepbound, Reyvow, Emgality |
| Otsuka America Pharmaceutical, INC. | $98.86 | 2023-2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $98.16 | 2024 | Voquezna |
| Radius Health, INC. | $95.64 | 2021-2025 | Tymlos |
| Biohaven Pharmaceuticals, INC. | $80.63 | 2021 | |
| Philips North America LLC | $77.01 | 2023-2025 | Ecc Solutions |
| Mannkind Corporation | $75.90 | 2022-2024 | Afrezza |
| Noven Therapeutics, LLC | $73.18 | 2023-2025 | Xelstrym |
| Allergan, INC. | $69.90 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $61.75 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $61.65 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.68 | 2019-2020 | |
| Dexcom, INC. | $53.21 | 2021-2025 | Dexcom G6 Transmitter |
| Zealand Pharma US, INC. | $51.61 | 2021-2022 | |
| Eisai INC. | $51.45 | 2020-2025 | |
| Seqirus USA INC | $50.75 | 2022-2024 | Fluad Quadrivalent, Flucelvax Quadrivalent, Fluad |
| Sanofi-Aventis U.S. LLC | $46.19 | 2021-2022 | |
| Kyowa Kirin, INC. | $44.81 | 2023 | Crysvita |
| Supernus Pharmaceuticals, INC. | $43.16 | 2019 | |
| Lundbeck LLC | $42.33 | 2024-2025 | Rexulti |
| Cepheid | $42.03 | 2024 | Genexpert |
| Biogen, INC. | $41.03 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.42 | 2025 | Caplyta |
| Nestle Healthcare Nutrition INC. | $39.40 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $36.52 | 2023 | Gemtesa |
| Arbor Pharmaceuticals, INC. | $35.49 | 2019 | |
| Abbott Laboratories | $31.59 | 2023-2025 | Freestyle Libre |
| Medtronic, INC. | $31.35 | 2022-2024 | Kyphon Express II Kyphopak Tray |
| Ultragenyx Pharmaceutical INC. | $31.16 | 2020-2021 | |
| Edwards Lifesciences Corporation | $26.97 | 2025 | Sapien 3 Ultra Resilia |
| Xeris Pharmaceuticals, INC. | $20.90 | 2023 | Gvoke Hypopen |
| Verona Pharma, INC. | $19.09 | 2025 | Ohtuvayre |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.74 | 2023 | |
| Novavax INC | $18.21 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Ibsa Pharma INC. | $14.30 | 2025 | Licart, Flector, Tirosint |
| Sanofi Pasteur INC. | $13.83 | 2025 | |
| Esperion Therapeutics, INC. | $13.59 | 2021 | |
| Ascensia Diabetes Care US INC. | $13.38 | 2023 | |
| Exact Sciences Corporation | $13.07 | 2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $12.96 | 2023 | Quviviq |
| Hikma Pharmaceuticals USA | $11.43 | 2020 | |
| Nevro Corp. | $11.09 | 2021 | |
| Alexion Pharmaceuticals, INC. | $10.97 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $3.76 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Deeves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.